English

Niki BioSolutions, Inc.

EDGAR

APM Current report (8-K) · filed 2026-10-13

118 filing records in this dataset, filed from 2018-09-05 to 2026-10-13. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

431 thousand USD

2023 · USD

Exact inputs and evidence

Revenue: 431378 USD Source

Net margin

-654.8%

2023 · %

Exact inputs and evidence

Net Income: -2824647 USD Source
Revenue: 431378 USD Source

Operating cash flow

-7.72 million USD

2023 · USD

Exact inputs and evidence

Operating Cash Flow: -7724364 USD Source

Free cash flow

-7.73 million USD

2023 · USD

Exact inputs and evidence

Operating Cash Flow: -7724364 USD Source
Capital Expenditure: 3015 USD Source

Cash and cash equivalents: 3.45 million USD 2025-12-31 Source
Exact value

3452891 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-13.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2023-12-31
operating income: No compatible figures in this window
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2023-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 2.9 million

Prior period

−USD 4.27 million

2024-01-01 – 2024-12-31
Current period

−USD 1.36 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-1363270 − -4267806 = 2904536 USD

-4267806 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-1363270 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Niki BioSolutions, Inc. · 2025-12-31 Niki BioSolutions, Inc. (edgar:1734005) Year-over-year change in Net income: 2904536 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -1363270 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#241774 Filing: 000121390026056820 Input fundies:NetIncome: -4267806 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#241892 Filing: 000121390026056820
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 646,812

Prior period

−USD 1.19 million

2024-01-01 – 2024-12-31
Current period

−USD 1.84 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-1836546 − -1189734 = -646812 USD

-1189734 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-1836546 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Niki BioSolutions, Inc. · 2025-12-31 Niki BioSolutions, Inc. (edgar:1734005) Year-over-year change in Operating cash flow: -646812 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -1836546 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#370271 Filing: 000121390026056820 Input fundies:OperatingCashFlow: -1189734 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#275558 Filing: 000121390026056820
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2023 2023-01-01 – 2023-12-31

Revenue USD 431,378 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income −USD 2.82 million −655% of revenue

Cash

Operating cash flow −USD 7.72 million −1,791% of revenue
Capital expenditure USD 3,015 0.7% of revenue
Free cash flow Derived −USD 7.73 million −1,791% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	1541778	Unavailable	Unavailable	Unavailable	-25048389	-14783383 Derived	Source 2021-01-01 – 2021-12-31: 1541778 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -25048389 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -14651633 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 131750 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	1295889	Unavailable	Unavailable	Unavailable	-9799560	-12505881 Derived	Source 2022-01-01 – 2022-12-31: 1295889 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -9799560 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -12318965 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 186916 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	431378	Unavailable	Unavailable	Unavailable	-2824647	-7727379 Derived	Source 2023-01-01 – 2023-12-31: 431378 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -2824647 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -7724364 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 3015 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 431.4K 2023

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	1541778	Revenue: 1541778 Open source
20222022-12-31	Revenue	1295889	Revenue: 1295889 Open source
20232023-12-31	Revenue	431378	Revenue: 431378 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-66.7% 2023

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 1541778 Open source
20222022-12-31	Year over year	-15.9%	Revenue: 1295889 Open source Revenue: 1541778 Open source
20232023-12-31	Year over year	-66.7%	Revenue: 431378 Open source Revenue: 1295889 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Net margin -654.8% 2023

Free cash flow margin -1,791.3% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2021-12-31	Operating margin	Not reported	Revenue: 1541778 Open source
2022-12-31	Operating margin	Not reported	Revenue: 1295889 Open source
2023-12-31	Operating margin	Not reported	Revenue: 431378 Open source
20212021-12-31	Net margin	-1,624.6%	Net Income: -25048389 Open source Revenue: 1541778 Open source
20222022-12-31	Net margin	-756.2%	Net Income: -9799560 Open source Revenue: 1295889 Open source
20232023-12-31	Net margin	-654.8%	Net Income: -2824647 Open source Revenue: 431378 Open source
20212021-12-31	Free cash flow margin	-958.9%	Revenue: 1541778 Open source Operating Cash Flow: -14651633 Open source Capital Expenditure: 131750 Open source
20222022-12-31	Free cash flow margin	-965%	Revenue: 1295889 Open source Operating Cash Flow: -12318965 Open source Capital Expenditure: 186916 Open source
20232023-12-31	Free cash flow margin	-1,791.3%	Revenue: 431378 Open source Operating Cash Flow: -7724364 Open source Capital Expenditure: 3015 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -7.7M 2023

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-14651633	Operating Cash Flow: -14651633 Open source
20222022-12-31	Operating cash flow	-12318965	Operating Cash Flow: -12318965 Open source
20232023-12-31	Operating cash flow	-7724364	Operating Cash Flow: -7724364 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -7.7M 2023

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-14783383	Operating Cash Flow: -14651633 Open source Capital Expenditure: 131750 Open source
20222022-12-31	Free cash flow	-12505881	Operating Cash Flow: -12318965 Open source Capital Expenditure: 186916 Open source
20232023-12-31	Free cash flow	-7727379	Operating Cash Flow: -7724364 Open source Capital Expenditure: 3015 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

25.5% 2023

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	20.1%	Total Liabilities: 4401121 Open source Total Assets: 21907243 Open source
20222022-12-31	Liabilities / assets	62.5%	Total Liabilities: 13034066 Open source Total Assets: 20867371 Open source
20232023-12-31	Liabilities / assets	25.5%	Total Liabilities: 5256738 Open source Total Assets: 20640091 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.18× 2023

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	2.9×	Current Assets: 12688300 Open source Current Liabilities: 4377268 Open source
20222022-12-31	Current assets / current liabilities	0.57×	Current Assets: 7067802 Open source Current Liabilities: 12503282 Open source
20232023-12-31	Current assets / current liabilities	1.18×	Current Assets: 2476092 Open source Current Liabilities: 2098753 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 14.83 million Exact value Exact value: -14831723 USD 2018-01-01 – 2018-12-31: -14831723 USD Inspect Net Income Open source Share or cite Citation for Net Income · Niki BioSolutions, Inc. · 2018-12-31 Niki BioSolutions, Inc. (edgar:1734005) Net Income: -14831723 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14831723 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390021021984/apm-20201231.xml#168303 Filing: 000121390021021984 The citation records this snapshot. The page link may show a newer release later.	−USD 10.04 million Exact value Exact value: -10035531 USD 2018-01-01 – 2018-12-31: -10035531 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Niki BioSolutions, Inc. · 2018-12-31 Niki BioSolutions, Inc. (edgar:1734005) Operating Cash Flow: -10035531 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10035531 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390021021984/apm-20201231.xml#218095 Filing: 000121390021021984 The citation records this snapshot. The page link may show a newer release later.	USD 5.65 million Exact value Exact value: 5646505 USD 2018-01-01 – 2018-12-31: 5646505 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Niki BioSolutions, Inc. · 2018-12-31 Niki BioSolutions, Inc. (edgar:1734005) Capital Expenditure: 5646505 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5646505 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390021021984/apm-20201231.xml#219435 Filing: 000121390021021984 The citation records this snapshot. The page link may show a newer release later.	−USD 15.68 million Calculation and evidence -10035531 − 5646505 USD Exact free cash flow: -15682036 USD 2018-01-01 – 2018-12-31: -10035531 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 5646505 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Niki BioSolutions, Inc. · 2018-12-31 Niki BioSolutions, Inc. (edgar:1734005) Free cash flow: -15682036 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10035531 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390021021984/apm-20201231.xml#218095 Filing: 000121390021021984 Input fundies:CapitalExpenditure: 5646505 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390021021984/apm-20201231.xml#219435 Filing: 000121390021021984 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 20.12 million Exact value Exact value: -20116938 USD 2019-01-01 – 2019-12-31: -20116938 USD Inspect Net Income Open source Share or cite Citation for Net Income · Niki BioSolutions, Inc. · 2019-12-31 Niki BioSolutions, Inc. (edgar:1734005) Net Income: -20116938 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20116938 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390023002916/f20f2021a1_aptorum.htm#1736427 Filing: 000121390023002916 The citation records this snapshot. The page link may show a newer release later.	−USD 13.38 million Exact value Exact value: -13382633 USD 2019-01-01 – 2019-12-31: -13382633 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Niki BioSolutions, Inc. · 2019-12-31 Niki BioSolutions, Inc. (edgar:1734005) Operating Cash Flow: -13382633 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -13382633 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390023002916/f20f2021a1_aptorum.htm#1767927 Filing: 000121390023002916 The citation records this snapshot. The page link may show a newer release later.	USD 837,062 Exact value Exact value: 837062 USD 2019-01-01 – 2019-12-31: 837062 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Niki BioSolutions, Inc. · 2019-12-31 Niki BioSolutions, Inc. (edgar:1734005) Capital Expenditure: 837062 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 837062 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390023002916/f20f2021a1_aptorum.htm#1771628 Filing: 000121390023002916 The citation records this snapshot. The page link may show a newer release later.	−USD 14.22 million Calculation and evidence -13382633 − 837062 USD Exact free cash flow: -14219695 USD 2019-01-01 – 2019-12-31: -13382633 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 837062 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Niki BioSolutions, Inc. · 2019-12-31 Niki BioSolutions, Inc. (edgar:1734005) Free cash flow: -14219695 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13382633 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390023002916/f20f2021a1_aptorum.htm#1767927 Filing: 000121390023002916 Input fundies:CapitalExpenditure: 837062 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390023002916/f20f2021a1_aptorum.htm#1771628 Filing: 000121390023002916 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 4.92 million Exact value Exact value: 4920167 USD 2020-01-01 – 2020-12-31: 4920167 USD Inspect Net Income Open source Share or cite Citation for Net Income · Niki BioSolutions, Inc. · 2020-12-31 Niki BioSolutions, Inc. (edgar:1734005) Net Income: 4920167 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 4920167 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390023033525/f20f2022_aptorumgroup.htm#1925231 Filing: 000121390023033525 The citation records this snapshot. The page link may show a newer release later.	−USD 15.93 million Exact value Exact value: -15931913 USD 2020-01-01 – 2020-12-31: -15931913 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Niki BioSolutions, Inc. · 2020-12-31 Niki BioSolutions, Inc. (edgar:1734005) Operating Cash Flow: -15931913 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15931913 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390023033525/f20f2022_aptorumgroup.htm#1954983 Filing: 000121390023033525 The citation records this snapshot. The page link may show a newer release later.	USD 161,314 Exact value Exact value: 161314 USD 2020-01-01 – 2020-12-31: 161314 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Niki BioSolutions, Inc. · 2020-12-31 Niki BioSolutions, Inc. (edgar:1734005) Capital Expenditure: 161314 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 161314 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390023033525/f20f2022_aptorumgroup.htm#1957636 Filing: 000121390023033525 The citation records this snapshot. The page link may show a newer release later.	−USD 16.09 million Calculation and evidence -15931913 − 161314 USD Exact free cash flow: -16093227 USD 2020-01-01 – 2020-12-31: -15931913 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 161314 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Niki BioSolutions, Inc. · 2020-12-31 Niki BioSolutions, Inc. (edgar:1734005) Free cash flow: -16093227 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15931913 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390023033525/f20f2022_aptorumgroup.htm#1954983 Filing: 000121390023033525 Input fundies:CapitalExpenditure: 161314 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390023033525/f20f2022_aptorumgroup.htm#1957636 Filing: 000121390023033525 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 25.05 million Exact value Exact value: -25048389 USD 2021-01-01 – 2021-12-31: -25048389 USD Inspect Net Income Open source Share or cite Citation for Net Income · Niki BioSolutions, Inc. · 2021-12-31 Niki BioSolutions, Inc. (edgar:1734005) Net Income: -25048389 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -25048389 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390024037520/ea0203681-20f_aptorum.htm#1508688 Filing: 000121390024037520 The citation records this snapshot. The page link may show a newer release later.	−USD 14.65 million Exact value Exact value: -14651633 USD 2021-01-01 – 2021-12-31: -14651633 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Niki BioSolutions, Inc. · 2021-12-31 Niki BioSolutions, Inc. (edgar:1734005) Operating Cash Flow: -14651633 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14651633 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390024037520/ea0203681-20f_aptorum.htm#1699669 Filing: 000121390024037520 The citation records this snapshot. The page link may show a newer release later.	USD 131,750 Exact value Exact value: 131750 USD 2021-01-01 – 2021-12-31: 131750 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Niki BioSolutions, Inc. · 2021-12-31 Niki BioSolutions, Inc. (edgar:1734005) Capital Expenditure: 131750 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 131750 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390024037520/ea0203681-20f_aptorum.htm#1702373 Filing: 000121390024037520 The citation records this snapshot. The page link may show a newer release later.	−USD 14.78 million Calculation and evidence -14651633 − 131750 USD Exact free cash flow: -14783383 USD 2021-01-01 – 2021-12-31: -14651633 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 131750 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Niki BioSolutions, Inc. · 2021-12-31 Niki BioSolutions, Inc. (edgar:1734005) Free cash flow: -14783383 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14651633 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390024037520/ea0203681-20f_aptorum.htm#1699669 Filing: 000121390024037520 Input fundies:CapitalExpenditure: 131750 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390024037520/ea0203681-20f_aptorum.htm#1702373 Filing: 000121390024037520 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 9.8 million Exact value Exact value: -9799560 USD 2022-01-01 – 2022-12-31: -9799560 USD Inspect Net Income Open source Share or cite Citation for Net Income · Niki BioSolutions, Inc. · 2022-12-31 Niki BioSolutions, Inc. (edgar:1734005) Net Income: -9799560 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9799560 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390025097467/ea0260563-6k_aptorum_htm.xml#214017 Filing: 000121390025097467 The citation records this snapshot. The page link may show a newer release later.	−USD 12.32 million Exact value Exact value: -12318965 USD 2022-01-01 – 2022-12-31: -12318965 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Niki BioSolutions, Inc. · 2022-12-31 Niki BioSolutions, Inc. (edgar:1734005) Operating Cash Flow: -12318965 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12318965 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390025097467/ea0260563-6k_aptorum_htm.xml#249353 Filing: 000121390025097467 The citation records this snapshot. The page link may show a newer release later.	USD 186,916 Exact value Exact value: 186916 USD 2022-01-01 – 2022-12-31: 186916 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Niki BioSolutions, Inc. · 2022-12-31 Niki BioSolutions, Inc. (edgar:1734005) Capital Expenditure: 186916 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 186916 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390025097467/ea0260563-6k_aptorum_htm.xml#249704 Filing: 000121390025097467 The citation records this snapshot. The page link may show a newer release later.	−USD 12.51 million Calculation and evidence -12318965 − 186916 USD Exact free cash flow: -12505881 USD 2022-01-01 – 2022-12-31: -12318965 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 186916 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Niki BioSolutions, Inc. · 2022-12-31 Niki BioSolutions, Inc. (edgar:1734005) Free cash flow: -12505881 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12318965 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390025097467/ea0260563-6k_aptorum_htm.xml#249353 Filing: 000121390025097467 Input fundies:CapitalExpenditure: 186916 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390025097467/ea0260563-6k_aptorum_htm.xml#249704 Filing: 000121390025097467 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 2.82 million Exact value Exact value: -2824647 USD 2023-01-01 – 2023-12-31: -2824647 USD Inspect Net Income Open source Share or cite Citation for Net Income · Niki BioSolutions, Inc. · 2023-12-31 Niki BioSolutions, Inc. (edgar:1734005) Net Income: -2824647 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2824647 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#242011 Filing: 000121390026056820 The citation records this snapshot. The page link may show a newer release later.	−USD 7.72 million Exact value Exact value: -7724364 USD 2023-01-01 – 2023-12-31: -7724364 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Niki BioSolutions, Inc. · 2023-12-31 Niki BioSolutions, Inc. (edgar:1734005) Operating Cash Flow: -7724364 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7724364 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#275735 Filing: 000121390026056820 The citation records this snapshot. The page link may show a newer release later.	USD 3,015 Exact value Exact value: 3015 USD 2023-01-01 – 2023-12-31: 3015 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Niki BioSolutions, Inc. · 2023-12-31 Niki BioSolutions, Inc. (edgar:1734005) Capital Expenditure: 3015 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3015 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#275912 Filing: 000121390026056820 The citation records this snapshot. The page link may show a newer release later.	−USD 7.73 million Calculation and evidence -7724364 − 3015 USD Exact free cash flow: -7727379 USD 2023-01-01 – 2023-12-31: -7724364 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 3015 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Niki BioSolutions, Inc. · 2023-12-31 Niki BioSolutions, Inc. (edgar:1734005) Free cash flow: -7727379 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7724364 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#275735 Filing: 000121390026056820 Input fundies:CapitalExpenditure: 3015 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#275912 Filing: 000121390026056820 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 4.27 million Exact value Exact value: -4267806 USD 2024-01-01 – 2024-12-31: -4267806 USD Inspect Net Income Open source Share or cite Citation for Net Income · Niki BioSolutions, Inc. · 2024-12-31 Niki BioSolutions, Inc. (edgar:1734005) Net Income: -4267806 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4267806 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#241892 Filing: 000121390026056820 The citation records this snapshot. The page link may show a newer release later.	−USD 1.19 million Exact value Exact value: -1189734 USD 2024-01-01 – 2024-12-31: -1189734 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Niki BioSolutions, Inc. · 2024-12-31 Niki BioSolutions, Inc. (edgar:1734005) Operating Cash Flow: -1189734 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1189734 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#275558 Filing: 000121390026056820 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 1.36 million Exact value Exact value: -1363270 USD 2025-01-01 – 2025-12-31: -1363270 USD Inspect Net Income Open source Share or cite Citation for Net Income · Niki BioSolutions, Inc. · 2025-12-31 Niki BioSolutions, Inc. (edgar:1734005) Net Income: -1363270 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1363270 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#241774 Filing: 000121390026056820 The citation records this snapshot. The page link may show a newer release later.	−USD 1.84 million Exact value Exact value: -1836546 USD 2025-01-01 – 2025-12-31: -1836546 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Niki BioSolutions, Inc. · 2025-12-31 Niki BioSolutions, Inc. (edgar:1734005) Operating Cash Flow: -1836546 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T03:06:20Z Snapshot: 22e04a13404b6cf5c2f4669e2c38cc1196397d6134a8a26f42a998e14a519550 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1734005/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1836546 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1734005/000121390026056820/ea0290494-01_htm.xml#370271 Filing: 000121390026056820 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

118 filings · 769 latest values · 769 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001734005, 1734005, APM, NIKI, edgar:1734005

Also known as APTORUM GROUP LIMITED, Aptorum Group Limited, Aptorum Group Ltd, Niki BioSolutions, Inc.

Niki BioSolutions, Inc.

Latest fiscal year

Revenue

Net margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2023 2023-01-01 – 2023-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation